These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

917 related articles for article (PubMed ID: 32293003)

  • 21. Discovery and characterization of ACE2 - a 20-year journey of surprises from vasopeptidase to COVID-19.
    Hooper NM; Lambert DW; Turner AJ
    Clin Sci (Lond); 2020 Sep; 134(18):2489-2501. PubMed ID: 32990314
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Angiotensin-Converting Enzyme Gene Polymorphism and Severe Lung Injury in Patients with Coronavirus Disease 2019.
    Zheng H; Cao JJ
    Am J Pathol; 2020 Oct; 190(10):2013-2017. PubMed ID: 32735889
    [TBL] [Abstract][Full Text] [Related]  

  • 23. SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy.
    Chung MK; Karnik S; Saef J; Bergmann C; Barnard J; Lederman MM; Tilton J; Cheng F; Harding CV; Young JB; Mehta N; Cameron SJ; McCrae KR; Schmaier AH; Smith JD; Kalra A; Gebreselassie SK; Thomas G; Hawkins ES; Svensson LG
    EBioMedicine; 2020 Aug; 58():102907. PubMed ID: 32771682
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systematic review of the role of renin-angiotensin system inhibitors in late studies on Covid-19: A new challenge overcome?
    Volpe M; Battistoni A
    Int J Cardiol; 2020 Dec; 321():150-154. PubMed ID: 32738257
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potential harmful effects of discontinuing ACE-inhibitors and ARBs in COVID-19 patients.
    Rossi GP; Sanga V; Barton M
    Elife; 2020 Apr; 9():. PubMed ID: 32250244
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis.
    Pirola CJ; Sookoian S
    J Infect; 2020 Aug; 81(2):276-281. PubMed ID: 32474043
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Renin-angiotensin system inhibitors improve the clinical outcomes of COVID-19 patients with hypertension.
    Meng J; Xiao G; Zhang J; He X; Ou M; Bi J; Yang R; Di W; Wang Z; Li Z; Gao H; Liu L; Zhang G
    Emerg Microbes Infect; 2020 Dec; 9(1):757-760. PubMed ID: 32228222
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cardiovascular Disease and Use of Renin-Angiotensin System Inhibitors in COVID-19.
    Kow CS; Zaidi STR; Hasan SS
    Am J Cardiovasc Drugs; 2020 Jun; 20(3):217-221. PubMed ID: 32281055
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential differential effects of renin-angiotensin system inhibitors on SARS-CoV-2 infection and lung injury in COVID-19.
    Furuhashi M; Moniwa N; Takizawa H; Ura N; Shimamoto K
    Hypertens Res; 2020 Aug; 43(8):837-840. PubMed ID: 32433641
    [No Abstract]   [Full Text] [Related]  

  • 30. Renin-angiotensin system inhibitors and the severity of coronavirus disease 2019 in Kanagawa, Japan: a retrospective cohort study.
    Matsuzawa Y; Ogawa H; Kimura K; Konishi M; Kirigaya J; Fukui K; Tsukahara K; Shimizu H; Iwabuchi K; Yamada Y; Saka K; Takeuchi I; Hirano T; Tamura K
    Hypertens Res; 2020 Nov; 43(11):1257-1266. PubMed ID: 32820236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019.
    Sanchis-Gomar F; Lavie CJ; Perez-Quilis C; Henry BM; Lippi G
    Mayo Clin Proc; 2020 Jun; 95(6):1222-1230. PubMed ID: 32376099
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Renin-angiotensin-aldosterone system and COVID-19 infection.
    Alexandre J; Cracowski JL; Richard V; Bouhanick B;
    Ann Endocrinol (Paris); 2020 Jun; 81(2-3):63-67. PubMed ID: 32370986
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Use of Renin-Angiotensin System Blockers During the COVID-19 Pandemic: Early Guidance and Evolving Evidence.
    Turgeon RD; Zieroth S; Bewick D; Chow CM; Clarke B; Cowan S; Fordyce CB; Fournier A; Gin K; Gupta A; Hardiman S; Jackson S; Lau B; Leong-Poi H; Mansour S; Marelli A; Quraishi AR; Roifman I; Ruel M; Sapp J; Singh G; Small G; Virani S; Wood DA; Krahn A
    Can J Cardiol; 2020 Aug; 36(8):1180-1182. PubMed ID: 32502522
    [No Abstract]   [Full Text] [Related]  

  • 34. [Renin-Angiotensin-System (RAS) and COVID-19 - On The Prescription of RAS Blockers].
    Kreutz R; Abd El-Hady Algharably E; Ganten D; Messerli F
    Dtsch Med Wochenschr; 2020 May; 145(10):682-686. PubMed ID: 32323279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)--The BRACE CORONA Trial.
    Lopes RD; Macedo AVS; de Barros E Silva PGM; Moll-Bernardes RJ; Feldman A; D'Andréa Saba Arruda G; de Souza AS; de Albuquerque DC; Mazza L; Santos MF; Salvador NZ; Gibson CM; Granger CB; Alexander JH; de Souza OF;
    Am Heart J; 2020 Aug; 226():49-59. PubMed ID: 32502882
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sound Science before Quick Judgement Regarding RAS Blockade in COVID-19.
    Sparks MA; South A; Welling P; Luther JM; Cohen J; Byrd JB; Burrell LM; Batlle D; Tomlinson L; Bhalla V; Rheault MN; Soler MJ; Swaminathan S; Hiremath S
    Clin J Am Soc Nephrol; 2020 May; 15(5):714-716. PubMed ID: 32220930
    [No Abstract]   [Full Text] [Related]  

  • 37. The interaction of RAAS inhibitors with COVID-19: Current progress, perspective and future.
    Zhang J; Wang M; Ding W; Wan J
    Life Sci; 2020 Sep; 257():118142. PubMed ID: 32712300
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RAAS blockers in hypertension posing a higher risk toward the COVID-19.
    Singh Y; Gupta G; Satija S; Negi P; Chellappan DK; Dua K
    Dermatol Ther; 2020 Jul; 33(4):e13501. PubMed ID: 32359088
    [No Abstract]   [Full Text] [Related]  

  • 39. Renin-Angiotensin System Inhibitors and COVID-19: a Systematic Review and Meta-Analysis. Evidence for Significant Geographical Disparities.
    Patoulias D; Katsimardou A; Stavropoulos K; Imprialos K; Kalogirou MS; Doumas M
    Curr Hypertens Rep; 2020 Sep; 22(11):90. PubMed ID: 32910274
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacotherapy in COVID-19 patients: a review of ACE2-raising drugs and their clinical safety.
    Akhtar S; Benter IF; Danjuma MI; Doi SAR; Hasan SS; Habib AM
    J Drug Target; 2020; 28(7-8):683-699. PubMed ID: 32700580
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.